HomeNYMXF • OTCMKTS
Nymox Pharmaceutical Corp
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 788.00K | -83.75% |
Net income | -857.00K | 83.86% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -788.00K | 83.74% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 74.00K | 5.71% |
Total assets | 654.00K | 4.31% |
Total liabilities | 7.43M | 95.50% |
Total equity | -6.78M | — |
Shares outstanding | 94.54M | — |
Price to book | -1.02 | — |
Return on assets | -308.29% | — |
Return on capital | 54.88% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -857.00K | 83.86% |
Cash from operations | -717.00K | 20.07% |
Cash from investing | — | — |
Cash from financing | 750.00K | -15.82% |
Net change in cash | 33.00K | 650.00% |
Free cash flow | -555.25K | -177.20% |
Previous close
$0.072
Day range
$0.072 - $0.086
Year range
$0.00010 - $1.40
Market cap
6.92M USD
Avg Volume
12.65K
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
About
Founded
1989
Website
Employees
3
